WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Global Chemical Company L.L.C.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
PHARMACY MARKET
Titan Pharmaceuticals, Inc. | December 22, 2021
Titan Pharmaceuticals, Inc. announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the Co...
WBRZ- | March 30, 2020
Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...
BUSINESS INSIGHTS
Element and Temasek | July 08, 2022
Element Materials Technology a global leader in testing, inspection, and certification services, has completed its acquisition by Temasek, a global investor headquartered in Singapore. Temasek has been a minority shareholder in Element since 2019. Temasek has acquired Element from Bridgepoint, whose successful ownership has been an important part of a more than ten-fold increase in Element’s turnover over the past decade. The acquisition, which was subject to regulatory approvals, was prev...
Sutro Biopharma, Inc.; Astellas Pharma Inc. | June 28, 2022
Astellas Pharma Inc. and Sutro Biopharma, Inc. announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates. The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise. “We are delighted t...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE